Continuous Flow in the High Desert: Tales from Los Alamos National Laboratory
Explore the source record for details and available documents.
Engineering topics
Publications and source records attributed to Evans, Amanda Christine.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Researchers at Los Alamos have invented a novel flow/batch chemistry synthetic process to produce the small molecule anti-viral favipiravir more cheaply and rapidly to enable on-demand production for pandemic response. Current methods for synthesizing favipiravir are constrained by long reaction times and low yields. If ongoing clinical trials for favipiravir demonstrate its effectiveness as a COVID-19 antiviral, and as a broad spectrum anti-viral for treating future viral outbreaks, this synthesis would help alleviate potential drug shortages and supply chain issues for the manufacturing and availability of this small molecule anti-viral. This U.S.-based synthesis route would be capable of scale-up for making large (kilogram) amounts of favipiravir as needed to assist with clinical trial needs and demand for patient treatment, and can also produce isotopically labeled favipiravir. We are seeking a CRADA partner to finalize method development who has interest in licensing the method and employing it for domestic production.